Overview of venous leg ulcers:
Venous leg ulcers are open wounds that form between the knee and ankle due to underlying venous disease. They are the most common type of leg ulcer, accounting for 60-80% of cases, with a prevalence of 0.18%-1% in the general population, increasing to 4% in those aged 65 years and older. Approximately 33-60% of VLUs last for more than 6 weeks and become chronic. These ulcers are the most advanced stage of chronic venous diseases such as varicose veins and lipodermatosclerosis.
Several risk factors contribute to the development of VLUs, including older age, female gender, obesity, trauma, immobility, congenital venous anomalies, deep venous thrombosis (DVT), phlebitis, and factor V Leiden mutation. On physical examination, venous ulcers are irregular and shallow, often occurring over bony prominences. Their base is usually composed of granulation tissue and fibrin, and associated symptoms may include varicose veins, edema, venous dermatitis, and lipodermatosclerosis. VLUs often recur and can take weeks to years to heal. Severe complications may include cellulitis, osteomyelitis, and malignant transformation.
Poor prognosis is associated with increasing ulcer size and duration. Evidence-based treatment strategies include leg elevation, compression therapy, wound dressings, pentoxifylline, and aspirin therapy. Surgical intervention may be considered if the ulcer is large, persistent, or refractory to conservative treatments.
Request a Full Insights Report on Venous Leg Ulcers Pipeline Insights: https://www.delveinsight.com/report-store/venous-leg-ulcers-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
"Venous Leg Ulcer Pipeline Insights 2025"DelveInsight's report provides a comprehensive analysis of the ongoing clinical development activities and growth prospects in the venous leg ulcer treatment market.
Key Takeaways from the Venous Leg Ulcers Pipeline Report:
DelveInsight's venous leg ulcer pipeline report focuses on a dynamic sector with over seven active players working on developing over seven pipeline therapies for the treatment of VLUs.
Key companies such as Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma and RHEACELL are actively evaluating new drugs to improve the treatment landscape for VLUs.
Promising treatments in various stages of development include ENERGI-F703, EscharEx, and others.
Recent advances in the venous leg ulcer pipeline:
A multicenter, randomized, self-controlled trial published in the International Wound Journal in 2023 demonstrated that the Geko™ device, when used alongside standard of care, significantly improved healing rates for difficult-to-heal VLUs, more than doubling healing rates compared to standard of care alone.
Venous Leg Ulcers Pipeline Analysis:
This report provides insights into:
- Key companies developing therapies in the venous leg ulcer market.
- Treatment candidates are categorized by development stage (early, mid, or late stage).
- Key players involved in targeted therapeutics development, including both active and inactive (dormant or discontinued) projects.
- New drugs under development, including stage of development, route of administration, target receptors, monotherapy or combination therapy, mechanism of action, and type of molecule.
- A detailed analysis of collaborations (company-company and company-academia collaborations), licensing agreements, and funding for future advancements in the Venous Leg Ulcers market.
Download Free Sample Page Report on Venous Leg Ulcers Pipeline Insights: https://www.delveinsight.com/sample-request/venous-leg-ulcers-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
New drugs for venous leg ulcers:
- Energy-F703: Energenesis Biomedical
- Escher-Ex: Mediwound
Venous Leg Ulcer Companies:
More than seven major companies are actively developing treatments for venous leg ulcers, with EnerGenesis Biomedical having drug candidates in the most advanced stages of development, specifically Phase II.
DelveInsight's report covers around seven+ products across various stages of clinical development.
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early stage products (Phase I) with the following details:
- Preclinical and discovery stage candidates
- Discontinued and inactive candidates
The Venous Leg Ulcers Pipeline report provides a therapeutic assessment of pipeline drugs by route of administration. The products are classified into various ROAs such as:
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Venous Leg Ulcer ProductsThey are classified according to the type of molecule:
- Monoclonal antibodies
- Low molecular weight
- peptide
Download the sample page to get a detailed assessment of emerging Venous Leg Ulcer Therapeutics and key players.: https://www.delveinsight.com/report-store/venous-leg-ulcers-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Pipeline Therapies Evaluated for Venous Leg Ulcers:
- Rating by Product Type
- Graded evaluation
- Evaluation by route of administration
- Evaluation by molecular type
To know more about the Venous Leg Ulcer Treatment market, download the Venous Leg Ulcers sample report.: https://www.delveinsight.com/sample-request/venous-leg-ulcers-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
table of contents
- Introduction to the report
- Executive Summary
- Current Treatment Patterns for Venous Leg Ulcers
- Venous Leg Ulcers – A DelveInsight Perspective
- Treatment evaluation
- Late-stage products (Phase III) for venous leg ulcers
- Venous Leg Ulcer Mid-stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage products
- Inactive Products
- Dormant products
- Discontinued Venous Leg Ulcer Products
- Venous Leg Ulcers Product Profile
- Major Venous Leg Ulcer Players
- Main products for venous leg ulcers
- Inactive and Discontinued Products
- Unmet Needs in Venous Leg Ulcers
- Future outlook for venous leg ulcers
- Analyst Review of Venous Leg Ulcers
- Appendix
- Reporting Methods
About DelveInsight
DelveInsight is a market research and consulting company specializing in the healthcare and life sciences sector, providing accurate market intelligence to support clients' business strategies. Our team of experienced experts analyzes the latest trends in the pharmaceutical, medical technology and biotechnology sectors and provides optimal solutions to companies across the globe.
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
